PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bioo Scientific

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bioo Scientific and Jungwoo F&B to Collaborate to Improve Cancer Diagnosis and Treatment - Bioo Scientific, Jungwoo F&B and the UT Gyeonggi Innovation Program are collaborating to enhance cancer diagnosis and treatment
Bioo Scientific and Jungwoo F&B to Collaborate to Improve Cancer Diagnosis and Treatment

 

NewswireToday - /newswire/ - Austin, TX, United States, 2011/09/26 - Bioo Scientific, Jungwoo F&B and the UT Gyeonggi Innovation Program are collaborating to enhance cancer diagnosis and treatment.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioo Scientific has been invited to be a guest of The University of Texas at Austin for the UT Gyeonggi Innovation Program which is being sponsored by Governor Kim Moon-Soo, of the Gyeonggi Province, Korea. The UT Gyeonggi Innovation Program is a 3-year program to promote entrepreneurship, identify promising technology start-up companies and introduce them to the United States market. The UT Gyeonggi Innovation Program is being operated through the Global Commercialization Group unit of the IC² Institute, which is part of The University of Texas at Austin. Their mission is to help establish foreign collaborations in science and biotechnology that create economic development opportunities for both Korean and US companies. Through this program, Bioo Scientific, a biotech company based in Austin, Texas, will work with Jungwoo F&B, an industrial automation leader in South Korea, to improve physicians’ ability to make diagnosis and treatment decisions for cancer patients by allowing more sensitive analysis of microRNAs and peptides in tumor samples.

Jungwoo F&B has developed the Image Oriented Navigation Laser Microdissection Device (ION LMD), which is a novel instrument for enhanced imaging and precise dissection of cells. Molecular pathologists can take advantage of this technology combination to provide superior laser dissection results. According to Donna Kidwell, the Global Program Manager for the IC² Institute,“Jungwoo F&B was selected in an innovation competition - our market research indicated that it was a novel approach to LMD and could be an enabling technology for molecular pathology. Our goal is to help such technologies commercialize successfully, and create strong international partnerships along the way.”

Bioo Scientific will work in conjunction with Jungwoo F&B to develop kits for the ION LMD system. Bioo Scientific has a line of NEXTflex™ Sequencing Kits that offers increased sensitivity, flexibility and speed for next-generation sequencing library preparation. Bioo Scientific also markets the MaxDiscovery™ kits for protein extraction and quantitation. Bioo Scientific will use their expertise in reagent development and manufacturing to introduce kits for global microRNA profiling and for protein extraction for mass spectroscopy-based peptide analysis of tumor samples. Dr Marianna Goldrick, who will be representing Bioo Scientific at Gyeonggi-UT Innovation Program Signing Ceremony, stated that “Bioo Scientific is enthusiastic about building a product line of kits designed to leverage the abilities of the ION Laser Microdissection Device developed by Jungwoo F&B. Their instrument provides significant technical advantages that will allow physicians and clinical researchers to bring the powerful technique of microdissection into routine use to improve diagnosis and treatment of cancer and other diseases.”

About Bioo Scientific Corporation
Founded in 2003, Bioo Scientific Corporation (biooscientific.com) is an Austin, TX based biotechnology company that provides innovative solutions to the life science and food safety industries. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 100 countries.

About JungWoo F&B
Founded in 1994, JungWoo F&B (ionlmd.com) is a recognized industrial automation leader in Korea, offering various linear motor products for the country's largest companies. It offers various factory automation products for clients in semiconductor, consumer electronics, LCD, automotive manufacturing and ship-building industries. In 2003, the company entered the bio-mechanics business for the medical laboratory market and developed an ION LMD system which is utilized in cancer research.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific and Jungwoo F&B to Collaborate to Improve Cancer Diagnosis and Treatment

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dawn Obermoeller - BiooScientific.com 
512-707-8993 dawno[.]biooscientific.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bioo Scientific / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)